P2P Call Guide

How to Win a P2P Call for Biologic Therapy (Autoimmune) Denied by Aetna

Payer-specific strategy, medical necessity arguments, and the exact phrases to use when Aetna denies Biologic Therapy (Autoimmune) (CPT J0135, J1745, J0717).

Why Aetna Denies Biologic Therapy (Autoimmune)

Step therapy not completed (conventional DMARDs first)

Prior biologic trial not documented

Biosimilar required before brand-name biologic

Know Aetna's Criteria

Aetna uses their own Clinical Policy Bulletins (CPBs) and InterQual criteria. CPBs are publicly available and numbered.

Key policies to know:

  • Clinical Policy Bulletins (CPBs) are publicly available and numbered
  • Uses eviCore for radiology and cardiology prior auth
  • Known for detailed, evidence-based CPBs with specific criteria
  • Precertification list updated annually

Aetna's Specific Approach to Biologic Therapy (Autoimmune)

Applicable Policy

Aetna CPB 0314 (Tumor Necrosis Factor Antagonists) or applicable CPB by drug class

How Aetna Typically Denies This

Aetna has very detailed CPBs for each biologic class with specific disease activity score requirements (DAS28 >3.2 for moderate RA, CDAI >10). They require documentation of these scores, not just a statement of active disease.

Your Strategy for This Payer

Calculate and document the exact disease activity score before the call. Aetna CPBs specify numeric thresholds -- meeting the number makes the approval straightforward. Missing the score is the most common denial reason.

Key Phrase to Use on the Call

"Per CPB 0314, the patient's [DAS28/CDAI/PASI] score of [X] exceeds the threshold for moderate-to-severe disease, confirming active disease despite [conventional DMARD] therapy."

Building Your Medical Necessity Argument

Document failure, intolerance, or contraindication to step therapy agents

Note disease activity scores (DAS28, CDAI, PASI)

If biosimilar switch requested, document clinical reason for brand

Reference comorbidities that limit alternative treatments

P2P Call Tips for Aetna

Reference the specific CPB number and criteria being met

Aetna CPBs are very detailed -- read them before the call

Address each specific criterion in the CPB during the P2P

Aetna medical directors are typically receptive to guideline-based arguments

Guidelines to Reference

  • ACR Guidelines for Rheumatoid Arthritis Treatment
  • AGA Guidelines for Biologic Therapy in IBD
  • AAD Guidelines for Biologic Therapy in Psoriasis

Relevant CPT Codes

CPT J0135CPT J1745CPT J0717

Specialty: Rheumatology / Gastroenterology / Dermatology

Want the full strategy?

The P2P Playbook covers payer-specific approaches for Biologic Therapy (Autoimmune) denied by Aetna -- plus 15 denial objections with word-for-word responses, what reviewers are actually thinking, and the 60-second prep framework. Written by a medical director who reviewed cases for major payers.

Get The P2P Playbook -- $39

Get a personalized P2P script in 60 seconds

Enter your specific case details and our AI generates a structured prep script tailored to Aetna's criteria.

More Biologic Therapy (Autoimmune) P2P Guides

More Aetna P2P Guides